Performance of the VitaPCR rapid molecular test for SARS-CoV-2 screening at hospital admission
Copyright © 2023 Elsevier Inc. All rights reserved..
OBJECTIVE: To evaluate the diagnostic accuracy of rapid VitaPCR™ (Credo) assay as screening test in emergency department (ED) patients prior to transfer or medical interventions.
METHODS: In this prospective study 6642 oropharyngeal swabs from nonpreselected ED patients were tested for SARS-CoV-2 with (1) extraction-free VitaPCR and (2) extraction-based reference assays (Aptima®, cobas®, Xpert®Xpress).
RESULTS: The median TAT of VitaPCR was 47 minutes (IQR: 38-59), while reference assays required 6.2 hours (IQR: 4.4-13.3). VitaPCR's sensitivity, specificity, PPV and NPV was 77.9%, 99.9%, 97.9%, and 98.9% in relation to Hologic Panther TMA; 78.3%, 99.8%, 96.4%, and 98.5% compared to Roche cobas6800 PCR; 71.2%, 99.2%, 94.9%, and 94.3% using Cepheid GeneXpert PCR as reference.
CONCLUSION: High-sensitivity testing is needed to limit nosocomial spread and identify asymptomatic COVID-19 patients. However, time advantage of the VitaPCR must be weighed against its significantly lower sensitivity, especially when used in high-risk environments such as hospitals.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:106 |
|---|---|
| Enthalten in: |
Diagnostic microbiology and infectious disease - 106(2023), 4 vom: 15. Aug., Seite 115974 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schuierer, Lukas [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 nucleic acid testing |
|---|
| Anmerkungen: |
Date Completed 03.07.2023 Date Revised 03.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.diagmicrobio.2023.115974 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357269926 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357269926 | ||
| 003 | DE-627 | ||
| 005 | 20231226072224.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.diagmicrobio.2023.115974 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1190.xml |
| 035 | |a (DE-627)NLM357269926 | ||
| 035 | |a (NLM)37224607 | ||
| 035 | |a (PII)S0732-8893(23)00084-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schuierer, Lukas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Performance of the VitaPCR rapid molecular test for SARS-CoV-2 screening at hospital admission |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.07.2023 | ||
| 500 | |a Date Revised 03.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a OBJECTIVE: To evaluate the diagnostic accuracy of rapid VitaPCR™ (Credo) assay as screening test in emergency department (ED) patients prior to transfer or medical interventions | ||
| 520 | |a METHODS: In this prospective study 6642 oropharyngeal swabs from nonpreselected ED patients were tested for SARS-CoV-2 with (1) extraction-free VitaPCR and (2) extraction-based reference assays (Aptima®, cobas®, Xpert®Xpress) | ||
| 520 | |a RESULTS: The median TAT of VitaPCR was 47 minutes (IQR: 38-59), while reference assays required 6.2 hours (IQR: 4.4-13.3). VitaPCR's sensitivity, specificity, PPV and NPV was 77.9%, 99.9%, 97.9%, and 98.9% in relation to Hologic Panther TMA; 78.3%, 99.8%, 96.4%, and 98.5% compared to Roche cobas6800 PCR; 71.2%, 99.2%, 94.9%, and 94.3% using Cepheid GeneXpert PCR as reference | ||
| 520 | |a CONCLUSION: High-sensitivity testing is needed to limit nosocomial spread and identify asymptomatic COVID-19 patients. However, time advantage of the VitaPCR must be weighed against its significantly lower sensitivity, especially when used in high-risk environments such as hospitals | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 nucleic acid testing | |
| 650 | 4 | |a Extraction-free | |
| 650 | 4 | |a Point-of-care testing | |
| 650 | 4 | |a Real-time polymerase chain reaction | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Kahn, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Messmann, Helmut |e verfasserin |4 aut | |
| 700 | 1 | |a Kling, Elisabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Römmele, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Hoffmann, Reinhard |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diagnostic microbiology and infectious disease |d 1986 |g 106(2023), 4 vom: 15. Aug., Seite 115974 |w (DE-627)NLM01262845X |x 1879-0070 |7 nnns |
| 773 | 1 | 8 | |g volume:106 |g year:2023 |g number:4 |g day:15 |g month:08 |g pages:115974 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.diagmicrobio.2023.115974 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 106 |j 2023 |e 4 |b 15 |c 08 |h 115974 | ||